Data from A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
Eleftheria Kalogera(Mayo Clinic), Matthew S. Block(Mayo Clinic in Arizona), Carrie Langstraat(Mayo Clinic in Arizona), Carrie Strand(Mayo Clinic), Sarah A. Buhrow(Mayo Clinic), Rachel A. Kudgus(Mayo Clinic), Andrea E. Wahner Hendrickson(Mayo Clinic in Arizona), Joel M. Reid(Children's Hospital of Philadelphia), Yiyi Yan(WinnMed), Laura Becher(Mayo Clinic), Gretchen Glaser(WinnMed), Wendy K. Nevala(Mayo Clinic), Heidi D. Finnes(Unknown), Aminah Jatoi(Mayo Clinic in Arizona), Jill M. Schimke(Mayo Clinic), Lisa A. Kottschade(Mayo Clinic in Arizona), Amanika Kumar(Mayo Clinic in Florida), Megan E. Grudem(Mayo Clinic), Vera J. Suman(Mayo Clinic in Arizona), Svetomir N. Markovic(Mayo Clinic in Arizona), Carolyn M. Klampe(Mayo Clinic), Liyi Geng(Mayo Clinic), S. John Weroha(Mayo Clinic), Robert R. McWilliams(Mayo Clinic in Arizona)
Cited by 0
Related Papers
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer
|Nature Genetics|2009|724
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33
|Nature Genetics|2010|614